| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Radhika S Joshi, Rolen Quadros, Michael Drumm, Rupasri Ain, Mitradas M Panicke. Sedative effect of Clozapine is a function of 5-HT European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 27. issue 1. 2018-02-12. PMID:27955831. |
sedative effect of clozapine is a function of 5-ht antipsychotic drugs are the mainstay in the treatment of schizophrenia and bipolar disorder. |
2018-02-12 |
2023-08-13 |
Not clear |
| Marina Šagu. Treatment-resistant schizophrenia: challenges and implications for clinical practice. Psychiatria Danubina. vol 27. issue 3. 2018-02-08. PMID:26400145. |
clozapine is recommended as first-line treatment for treatment-resistant schizophrenia (trs) in all guidelines. |
2018-02-08 |
2023-08-13 |
Not clear |
| Jessica L Gören, Adam J Rose, Ryann L Engle, Eric G Smith, Melissa L D Christopher, Nathaniel M Rickles, Todd P Semla, Megan B McCulloug. Organizational Characteristics of Veterans Affairs Clinics With High and Low Utilization of Clozapine. Psychiatric services (Washington, D.C.). vol 67. issue 11. 2018-01-31. PMID:27301765. |
clozapine is the only medication proven effective for treatment-resistant schizophrenia. |
2018-01-31 |
2023-08-13 |
Not clear |
| Jessica L Gören, Adam J Rose, Ryann L Engle, Eric G Smith, Melissa L D Christopher, Nathaniel M Rickles, Todd P Semla, Megan B McCulloug. Organizational Characteristics of Veterans Affairs Clinics With High and Low Utilization of Clozapine. Psychiatric services (Washington, D.C.). vol 67. issue 11. 2018-01-31. PMID:27301765. |
however, in most settings less than 25% of patients with treatment-resistant schizophrenia receive clozapine. |
2018-01-31 |
2023-08-13 |
Not clear |
| Jessica L Gören, Adam J Rose, Eric G Smith, John P Ne. The Business Case for Expanded Clozapine Utilization. Psychiatric services (Washington, D.C.). vol 67. issue 11. 2018-01-31. PMID:27301766. |
in most settings, less than 25% of patients with treatment-resistant schizophrenia receive clozapine, the only medication proven effective for treatment-resistant schizophrenia. |
2018-01-31 |
2023-08-13 |
Not clear |
| Jessica L Gören, Adam J Rose, Eric G Smith, John P Ne. The Business Case for Expanded Clozapine Utilization. Psychiatric services (Washington, D.C.). vol 67. issue 11. 2018-01-31. PMID:27301766. |
therefore, a business case analysis was conducted to assess whether increasing clozapine utilization for treatment-resistant schizophrenia in a health care system would result in direct health care cost savings. |
2018-01-31 |
2023-08-13 |
Not clear |
| Thomas E Winkler, Sarah L Lederer, Eunkyoung Kim, Hadar Ben-Yoav, Deanna L Kelly, Gregory F Payne, Reza Ghodss. Molecular processes in an electrochemical clozapine sensor. Biointerphases. vol 12. issue 2. 2018-01-25. PMID:28460529. |
one example is schizophrenia treatment monitoring of the redox-active antipsychotic clozapine. |
2018-01-25 |
2023-08-13 |
Not clear |
| Matteo Marcatili, Fabio Marsoner, Armando D'Agostino, Thodoris Karnavas, Daniele Bottai, Silvio Scarone, Luciano Cont. Establishment of an induced pluripotent stem cell (iPSC) line from a patient with Clozapine-responder Schizophrenia. Stem cell research. vol 17. issue 3. 2018-01-22. PMID:27934596. |
peripheral blood mononuclear cells (pbmcs) were collected from a patient with treatment-refractory schizophrenia who presented an exceptional clinical response to clozapine. |
2018-01-22 |
2023-08-13 |
Not clear |
| Matteo Marcatili, Fabio Marsoner, Armando D'Agostino, Thodoris Karnavas, Daniele Bottai, Silvio Scarone, Luciano Cont. Establishment of an induced pluripotent stem cell (iPSC) line from a patient with Clozapine-responder Schizophrenia. Stem cell research. vol 17. issue 3. 2018-01-22. PMID:27934596. |
this hipsc line represents a valuable tool to study the molecular, biochemical and electrophysiological properties of mature neuronal populations belonging to clozapine responder patients with a severe form of schizophrenia. |
2018-01-22 |
2023-08-13 |
Not clear |
| S E Legge, M L Hamshere, S Ripke, A F Pardinas, J I Goldstein, E Rees, A L Richards, G Leonenko, L F Jorskog, K D Chambert, D A Collier, G Genovese, I Giegling, P Holmans, A Jonasdottir, G Kirov, S A McCarroll, J H MacCabe, K Mantripragada, J L Moran, B M Neale, H Stefansson, D Rujescu, M J Daly, P F Sullivan, M J Owen, M C O'Donovan, J T R Walter. Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia. Molecular psychiatry. vol 22. issue 10. 2018-01-19. PMID:27400856. |
the antipsychotic clozapine is uniquely effective in the management of schizophrenia; however, its use is limited by its potential to induce agranulocytosis. |
2018-01-19 |
2023-08-13 |
human |
| Euitae Kim, Oliver D Howes, Mattia Veronese, Katherine Beck, Seongho Seo, Jin Woo Park, Jae Sung Lee, Yun-Sang Lee, Jun Soo Kwo. Presynaptic Dopamine Capacity in Patients with Treatment-Resistant Schizophrenia Taking Clozapine: An [ Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 42. issue 4. 2018-01-19. PMID:27857125. |
presynaptic dopamine capacity in patients with treatment-resistant schizophrenia taking clozapine: an [ some patients with schizophrenia show poor response to first-line antipsychotic treatments and this is termed treatment-resistant schizophrenia. |
2018-01-19 |
2023-08-13 |
human |
| Alp Üçok, Ugur Çıkrıkçılı, Ceylan Ergül, Öznur Tabak, Ada Salaj, Sercan Karabulut, Christoph U Correl. Correlates of Clozapine Use after a First Episode of Schizophrenia: Results From a Long-term Prospective Study. CNS drugs. vol 30. issue 10. 2018-01-17. PMID:27356920. |
correlates of clozapine use after a first episode of schizophrenia: results from a long-term prospective study. |
2018-01-17 |
2023-08-13 |
Not clear |
| Alp Üçok, Ugur Çıkrıkçılı, Ceylan Ergül, Öznur Tabak, Ada Salaj, Sercan Karabulut, Christoph U Correl. Correlates of Clozapine Use after a First Episode of Schizophrenia: Results From a Long-term Prospective Study. CNS drugs. vol 30. issue 10. 2018-01-17. PMID:27356920. |
earlier commencement of clozapine has been related to a better response in treatment-resistant schizophrenia. |
2018-01-17 |
2023-08-13 |
Not clear |
| Marise Wj Machielsen, Dick J Veltman, Wim van den Brink, Lieuwe de Haa. The effect of clozapine and risperidone on attentional bias in patients with schizophrenia and a cannabis use disorder: An fMRI study. Journal of psychopharmacology (Oxford, England). vol 28. issue 7. 2018-01-16. PMID:24646809. |
the effect of clozapine and risperidone on attentional bias in patients with schizophrenia and a cannabis use disorder: an fmri study. |
2018-01-16 |
2023-08-12 |
Not clear |
| Marise Wj Machielsen, Dick J Veltman, Wim van den Brink, Lieuwe de Haa. The effect of clozapine and risperidone on attentional bias in patients with schizophrenia and a cannabis use disorder: An fMRI study. Journal of psychopharmacology (Oxford, England). vol 28. issue 7. 2018-01-16. PMID:24646809. |
we compared the effects of clozapine and risperidone on attentional bias, subjective craving and associated regional brain activity in patients with schizophrenia and cud. |
2018-01-16 |
2023-08-12 |
Not clear |
| Marise Wj Machielsen, Dick J Veltman, Wim van den Brink, Lieuwe de Haa. The effect of clozapine and risperidone on attentional bias in patients with schizophrenia and a cannabis use disorder: An fMRI study. Journal of psychopharmacology (Oxford, England). vol 28. issue 7. 2018-01-16. PMID:24646809. |
these findings strongly suggest that clozapine may be a better treatment choice in patients with schizophrenia and cud than risperidone. |
2018-01-16 |
2023-08-12 |
Not clear |
| I Qurashi, J D Collins, I B Chaudhry, N Husai. Promising use of minocycline augmentation with clozapine in treatment-resistant schizophrenia. Journal of psychopharmacology (Oxford, England). vol 28. issue 7. 2018-01-16. PMID:24646811. |
promising use of minocycline augmentation with clozapine in treatment-resistant schizophrenia. |
2018-01-16 |
2023-08-12 |
Not clear |
| I Qurashi, J D Collins, I B Chaudhry, N Husai. Promising use of minocycline augmentation with clozapine in treatment-resistant schizophrenia. Journal of psychopharmacology (Oxford, England). vol 28. issue 7. 2018-01-16. PMID:24646811. |
treatment-resistant schizophrenia is a major health problem in the uk with the majority of patients treated with clozapine. |
2018-01-16 |
2023-08-12 |
Not clear |
| Alessandro Rimessi, Chiara Pavan, Elli Ioannidi, Federica Nigro, Claudia Morganti, Alberto Brugnoli, Francesco Longo, Chiara Gardin, Letizia Ferroni, Michele Morari, Vincenzo Vindigni, Barbara Zavan, Paolo Pinto. Protein Kinase C β: a New Target Therapy to Prevent the Long-Term Atypical Antipsychotic-Induced Weight Gain. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 42. issue 7. 2018-01-12. PMID:28128334. |
among them, clozapine is the most effective medication for treatment-resistant schizophrenia and is most helpful in controlling aggression and the suicidal behavior in schizophrenia and schizoaffective disorder. |
2018-01-12 |
2023-08-13 |
mouse |
| Ozhan Yalcin, Gizem Kaymak, Ayten Erdogan, Canan Tanidir, Gul Karacetin, Ali Guven Kilicoglu, Caner Mutlu, Hilal Adaletli, Hatice Gunes, Kayhan Bahali, Basak Ayik, Ozden Sukran Uner. A Retrospective Investigation of Clozapine Treatment in Autistic and Nonautistic Children and Adolescents in an Inpatient Clinic in Turkey. Journal of child and adolescent psychopharmacology. vol 26. issue 9. 2018-01-08. PMID:26771824. |
the aim of this retrospective study is to examine the clinical outcomes and safety of clozapine in children and adolescents with schizophrenia or other psychotic disorders/autism spectrum disorder (asd) or affective disorders. |
2018-01-08 |
2023-08-13 |
Not clear |